-
OUR MISSIONTo mimic human inflammation - to reduce animal testing in preclinical development Build customised assays for use in product development with a high translational capacity Continuously adapt and improve our platform based on client requirements
ADVANTAGES OF MESENFLOWEarly attrition of weaker projects Reduce cost, decrease lead times Redirect resources to more promising projects -
TRANSLATIONAL SOLUTIONSIN COSMETICS AND DRUG DEVELOPMENTHuman organoid technology Immune and cancer cell trafficking Acute and chronic inflammation High-throughput vascular flow Efficacy and toxicologyWHAT WE OFFERWe provide the world’s first increased-throughput inflammatory human tissue engineering system for use in drug and cosmetic preclinical development.
Our Solutions
A Translational Platform to Study Human Inflammation
Better Translation, Higher Throughput
We have developed a proprietary human tissue engineering system that mimics physiological aspects of inflammation.
Using bio-imaging, we can measure:
Recruitment Movement of leukocytes through blood vessel walls
Retention Blockade of leukocytes egress from inflammatory tissue
We can access clinical samples to explore processes in:
Acute toxicity
Chronic disease modeling
Leukocyte Recruitment
Leukocyte Retention
About MesenFlow
MesenFlow Technologies has developed a platform to meet the demands of modern drug development. It is a bio-imaging technology designed to accelerate the drug development process & provide solutions to problems associated with species cross-reactivity, animal testing & understanding human disease. This has been achieved by using proprietary protocols on primary human cells, allowing the mechanism of action & translational relevance of a drug to be defined very early on in the development process.
MesenFlow Technologies has recently extended this technology for use in cosmetics and nutrition. By using our technology, it is possible to explore the physiological impact of a cosmetic or nutraceutical candidate in the early development phase. Our services are particularly tailored to business environments where animal-free testing is mandatory, and an understanding of impact on human biology is paramount.
Our Team
Paul Bradfield PhD MBA, CEO.
Paul has over 20 years experience in Academia, large Pharma & Biotech. Previously he was a Project Leader & Laboratory Head at MerckSerono SA, where he was involved in early drug development in inflammatory diseases, as well as in developing translational medicine techniques. Under his management, MesenFlow Technologies has developed a platform with proven applications in cosmetics & accelerated drug development. He has over 20 publications & patents.
Professor Beat Imhof PhD, Scientific Adviser.
Beat is a Professor Emeritus in the Department of Pathology & Immunology, at the University of Geneva, where he was previously Head of Department. His continued research interests are in the pathology of leukocyte migration in inflammatory diseases & tumor angiogenesis, as well as in drug development. He has also held roles as President of the Swiss Society Allergology & Immunology, & European Society of Microcirculation. He has over 180 publications & patents.
Riccardo Nisato PhD MBA, Co-Founder.
Riccardo has over 20 years of experience in academic & industrial environments, & is a respected Biologist, Project Leader & Business Consultant in the medical technology field. He has held top management positions (e.g. CEO, Director manufacturing & Business Development, CSO) at LAM Biotechnologies, Elanix Biotechnologies, Genes-x, Stemedica International, CHUV, MMV, & EPFL. He has over 10 publications & patents.
Contact us
MesenFlow Technologies
Geneva, Switzerland
+41 22 32 16 961 (office)
+41 79 36 66 291 (mobile)